BioCentury
ARTICLE | Clinical News

FDA lifts Phase III Aptosyn trial hold

December 7, 2001 8:00 AM UTC

Cell Pathways (CLPA) said the FDA lifted its clinical hold on patient accrual in CLPA's U.S. double-blind, placebo-controlled Phase III trial of Aptosyn exisulind in combination with Taxotere docetaxe...